The Citizens Commission on Human Rights (CCHR) has called on consumers to scrutinize psychotropic drug labels for warnings about suicide, aggression, and homicidal ideation, and to demand that prescribing physicians explain these risks, even when they are listed as rare. The call follows recent news reports of violent crimes involving individuals who were taking or withdrawing from prescribed antidepressants, stimulants, or other psychiatric drugs. CCHR argues that such reports highlight a broader issue: patients should be fully informed about what regulators and manufacturers have disclosed about these drugs, and prescribers should ensure they understand the potential risks.
CCHR, an international mental health industry watchdog established in 1969 by the Church of Scientology and Dr. Thomas Szasz, has long campaigned for transparency regarding the adverse effects of psychiatric medications. Its efforts have contributed to regulatory warnings in the U.S. and abroad. Jan Eastgate, president of CCHR International, emphasized that "a rare warning buried in a package insert is not the same as a doctor explaining the risk to a patient. Listing a side effect as 'rare' does not establish that the patient was told about it, understood it, or agreed to take that risk. Meaningful informed consent requires meaningful disclosure and prescriber accountability."
The issue is also being debated in legal and professional arenas. A recent article in Psychiatric Times discussed whether psychiatrists should be held responsible for their patients' criminal behavior, referencing a high-profile murder case where the defense argued that psychiatric polypharmacy contributed to violent behavior. The journal noted that "a good portion of the public and the media appear to support the defense theory" and that the litigation "places psychiatrists and other mental health providers under scrutiny." The authors concluded that "psychiatry itself may end up on trial."
Drug labeling already provides examples of such warnings. For instance, homicidal ideation was added to the label for extended-release venlafaxine in 2005. In 2009, the FDA required a boxed neuropsychiatric warning for bupropion products, citing reports of hostility, agitation, aggression, psychosis, homicidal ideation, and suicidal events. In 2023, the FDA mandated class-wide labeling for CNS stimulants warning that "anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation" have been observed with misuse. Esketamine nasal spray labels instruct patients to seek medical attention for sudden mood changes, including acting aggressive or violent. The antipsychotic aripiprazole lists homicidal ideation as a rare adverse reaction in adults.
Despite these label warnings, CCHR argues that simply printing a warning does not guarantee a patient has seen or understood it. This concern has entered public policy, with a 2026 Tennessee law requiring toxicology testing for psychiatric drugs following specified violent incidents. CCHR has called for similar laws in every state.
Eastgate stressed that "drug labeling now contains warnings and adverse-event information that consumers have a right to know about. While not all individuals taking a prescription psychotropic drug will become violent or suicidal, they should read these warnings and ask questions before agreeing to treatment. Prescribers should explain potentially serious violent and suicidal adverse effects—including those considered rare—and document that the patient was given the information necessary to make an informed decision."
The implications for industry and healthcare are significant. For pharmaceutical companies, this could lead to more stringent labeling requirements and increased liability. For prescribers, it underscores the need for thorough patient communication and documentation. For patients, it reinforces the importance of being proactive in understanding the risks of their medications. CCHR also advises that patients should not abruptly stop taking psychiatric drugs; any changes should be managed with medical supervision.
As CCHR continues to advocate for transparency, the message is clear: informed consent must go beyond a signature on a form. It requires a genuine dialogue between patients and prescribers about the potential consequences of treatment, including rare but serious behavioral side effects.
